Clinical trial NCT01165450 - References

Persistent Corneal Epithelial Defects — Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects

Citation(s)

•   Lin JH, Weigel H, Cotrina ML, Liu S, Bueno E, Hansen AJ, Hansen TW, Goldman S, Nedergaard M
  Gap-junction-mediated propagation and amplification of cell injury. Nat Neurosci. 1998 Oct;1(6):494-500. Erratum in: Nat Neurosci 1998 Dec;1(8):743.
•   Qiu C, Coutinho P, Frank S, Franke S, Law LY, Martin P, Green CR, Becker DL
  Targeting connexin43 expression accelerates the rate of wound repair. Curr Biol. 2003 Sep 30;13(19):1697-703.

Phase 2, Randomized, Double-masked, Vehicle-controlled, Dose-escalation Study Evaluating Efficacy/Safety of Nexagon in Subjects With Persistent Corneal Epithelial Defects (PED) Resulting From Corneal Epithelial Debridement During Diabetic Vitrectomy Surgery, Herpes Simples Virus (HSV) Keratitis, Herpes Zoster Virus (HZV) Keratitis, Corneal Burns, Post-photorefractive Keratectomy (Post-PRK), or Post-corneal Transplant Surgery.

Details for clinical trial NCT01165450